{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.2","upperLimit":"28.6","value":"12.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"}],"units":"Participants"}],"description":"Duration of Response (DOR) was defined as the interval from the first documentation of CR or PR (or MR for participants with WM) to the earlier of the first documentation of disease progression as assessed by the study IRC or death from any cause. DOR was analyzed using Kaplan-Meier (KM) estimates.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"OG000","title":"Idelalisib"}],"paramType":"MEDIAN","populationDescription":"Participants in the ITT Analysis Set who achieved a CR or PR (or MR for participants with WM) were analyzed.","reportingStatus":"POSTED","timeFrame":"Start of Treatment to End of Treatment (up to 81 months)","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}